Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation?
Curt R Freed1, Maureen A Leehey, Michael Zawada
1Departments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine, 4200 East Ninth Avenue, C237, Denver, CO 80220, USA. Curt.Freed@uchsc.edu
Abstract:
Embryonic dopamine cell transplants survive in nearly all patients regardless of age and without immunosuppression. Transplants can improve Parkinson "off" symptoms up to the best effects of L-dopa observed preoperatively. They cannot improve the "best on" state. Transplants appear to survive indefinitely. In 10 to 15% of patients, transplants can reproduce the dyskinetic effects of L-dopa even after discontinuing all L-dopa. Neurotransplantation should be tried earlier in the clinical course of Parkinson's to see if earlier intervention can prevent progression of the disease, particularly the dyskinetic responses seen after longterm L-dopa treatment.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
EPS and iPS Cells in Disease Research
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...


